Yusuke Nakamura to Doxorubicin
This is a "connection" page, showing publications Yusuke Nakamura has written about Doxorubicin.
Connection Strength
0.441
-
PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents. Oncotarget. 2015 Oct 13; 6(31):30957-67.
Score: 0.126
-
[A case with an ovarian cancer patient who could receive anti-cancer therapy and palliative care simultaneously at home through seamless collaboration in healthcare linkage]. Gan To Kagaku Ryoho. 2010 Dec; 37 Suppl 2:253-5.
Score: 0.090
-
Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci. 2007 Jan; 98(1):113-7.
Score: 0.069
-
Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005 Apr 01; 11(7):2625-36.
Score: 0.061
-
Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol. 2004 Mar; 24(3):647-55.
Score: 0.056
-
Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses. J Hum Genet. 2004; 49(3):134-140.
Score: 0.014
-
hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci. 2003 May; 94(5):431-6.
Score: 0.013
-
Cyclin K as a direct transcriptional target of the p53 tumor suppressor. Neoplasia. 2002 May-Jun; 4(3):268-74.
Score: 0.012